The research division of Woman’s Hospital’s lab services conducts clinical and molecular biology/genetic research, including technical and administrative support, for the medical staff and community.
Our goal is to promote women's and infant's health research while enhancing medical care and improving patient outcomes. Research initiatives are chosen by their potential to ultimately improve the health care of women and infants in this region.
You can help be a part of our mission by participating in these studies. May we contact you about participating in our research programs? If so, contact Woman’s Hospital Research Department at 225-231-5275.
Woman's Hospital researchers collaborate with many researchers at institutions across the United States, including: American College of Surgeons Oncology Group, Gynecologic Oncology Group, Louisiana State University, Pennington Biomedical Research Institute, University of Washington at Seattle, and several pharmaceutical companies.
All research studies are submitted to Woman's Hospital’s Research and Development Council (R&D). The R&D is a multidisciplinary group of individuals, appointed by the Woman's Hospital Foundation Chair, to oversee clinical research at the hospital and to refer studies involving human subjects to the Woman's Hospital Foundation Institutional Review Board (IRB) for review.
In addition to research endeavors, the hospital’s research staff provides non-research services to Woman's Hospital and surrounding communities. These activities include:
- Molecular-based clinical diagnostic testing
- Program development and support
The PILL Study
Woman’s Hospital announces the PILL study to determine the effectiveness of a new, low-dose oral contraceptive containing folate (a B vitamin) in reducing excessive male hormone levels in women with Polycystic Ovary Syndrome (PCOS). PCOS, one of the most common endocrine disorders in reproductive age women, is characterized by elevated levels of male hormones (androgens) which often presents with symptoms such as facial and body hair, weight gain, and infertility.
The PILL Study is an open label, parallel-group study which means all women will be given the same oral contraceptives. The study will include 75 healthy, premenopausal women, ages 18 to 35 years with diagnosed PCOS who desire contraceptive therapy. All women must meet study requirements and will undergo clinical, metabolic, and lab evaluations before, during, and after the 6 month period to determine the pills’ effectiveness. For more information, patients may contact the Woman’s Hospital Research Department at 225-231-5275.
New Direction in Treatment for PCOS Study
Woman’s is launching a new 16-week study for women who have polycystic ovary syndrome (PCOS) and elevated blood sugar. The study will test the success of a new medicine that has been found to improve abnormal glucose (sugar) levels and reduce body weight.
36 participants are needed who meet the following criteria:18-42 years old with PCOS, have less than nine menstrual cycles a year, have elevated blood sugar, but not diabetic, nonsmoker and not pregnant or breastfeeding.
All participants will receive a 16-week supply of medication. Office visits and lab test will be included free of charge and participants will be compensated for their time. For more information, patients may contact the Woman’s Hospital Research Department at 225-231-5275.
Better Rx for GDM Study
While the elevated blood glucose (sugar) levels of gestational diabetes “goes away” after delivery, One out of every three women with gestational diabetes will battle “pre-diabetes” after her baby is born. This means that blood glucose levels are higher than normal. People with pre-diabetes are at a high risk of developing diabetes. Woman’s BetteRX Moms study will compare the effectiveness of different oral medicines in treating this condition.
BetteRX Moms must meet the following criteria: English-speaking women ages 18-24, had gestational diabetes during their last pregnancy, gave birth less than a year ago and diagnosed as pre-diabetic by an oral glucose (sugar) tolerance test.
Participants will receive the following at no charge: A personalized diet and exercise plan, physician office visits, lab testing and an oral medication for 16 weeks (randomly assigned medications include Sitagliptin plus Metformin (Janumet), Metformin or a placebo.) Participants will also be compensated for their time. For more information, patients may contact the Woman’s Hospital Research Department at 225-231-5275.
Study to Prevent Diabetes in Post-Pregnancy, Overweight Women with History of Gestational Diabetes
This new study will focus on preventing the onset of diabetes in overweight women with a history of gestational diabetes who delivered less than a year ago. In a double-blind placebo trial, for the next two years, Woman’s will monitor 150 women in order to determine the effectiveness of two drug combinations in stabilizing sugar and insulin levels and promoting weight loss. The medications are Metformin and Metformin in combination with Liraglutide, a long-acting glucagon-like peptide 1 (GLP-1) derivative administered once daily.
Combined Liraglutide and Metformin Therapy in Women with Previous Gestational Diabetes Mellitus will study overweight women who were diagnosed with GDM in their last pregnancy, have not returned to normal metabolic function, and remain overweight with diagnosed insulin problems. Participants must have delivered infants at Woman’s Hospital and had GDM within the past year, be 18-45 years old, and meet all additional study requirements. Participants will be compensated for their time in addition to receiving free medication, clinic visits with the physician, and testing.
Are you pregnant? If so, you may be eligible to participate in the LA Moms and Babies Study (LAMBS) for nutrition and growth. This research study evaluates how diet during pregnancy can benefit pregnancy and pregnancy outcome, such as your baby’s weight. Information gained from LAMBS will help us make the best nutrition and diet recommendations to pregnant women and women of child bearing ages.
You may be eligible to participate if you:
- Are pregnant
- 18-35 years old
Benefits to participants:
- General nutrition guidelines provided during study
- Summary of infant’s growth during first year of life
- Qualified study participants will earn up to $575 over the course of approximately 80 weeks.
To learn more, call 225-231-5275.